NBTX - CONSENSUS CO - Nanobiotix S.A.

Nanobiotix S.A. (NBTX) develops advanced nanomedicines to enhance the efficacy of tumor irradiation, which are currently undergoing final testing and preparing for commercialization. This Franco-American firm's operations rely on unique developments in radiology and partnerships with clinics. This historical price chart reflects the dynamics of the asset, which has a value of 56.63, while the business faces strict FDA oversight and patent restrictions.

The consensus forecast determines the asset's fundamental margin of safety through the weighted average expectation of analysts. This consensus valuation chart visualizes the gap between the current price and the fair value. The metric measures growth potential, identifying whether the security is undervalued or overbought. For Nanobiotix S.A. (NBTX), this indicator is critical due to high scientific development risks. It helps assess the value of technologies amidst competition with biotech behemoths.